Article

Rituximab for myasthenia gravis: three case reports and review of the literature.

Department of Neurology, Academic Teaching Hospital Wagner-Jauregg, Linz, Austria.
Journal of the neurological sciences (Impact Factor: 2.32). 06/2009; 280(1-2):120-2. DOI: 10.1016/j.jns.2009.02.357
Source: PubMed

ABSTRACT In generalized myasthenia gravis (MG), a wide array of immunosuppressive and immunomodulating treatments is being used in clinical practice, but most drugs lack evidence from randomized controlled trials supporting their use. Furthermore, many patients develop serious side effects or do not respond sufficiently to these drugs. We report three patients with generalized MG who were treated with rituximab, a monoclonal antibody against CD20+ cells that causes prolonged B cell depletion. In all three patients, treatment with rituximab led to a sustained clinical improvement and discontinuation or reduction of prednisolone and other drugs. Rituximab was well tolerated. Therapy with rituximab was guided by the total count of peripheral B lymphocytes. Reviewing the anecdotal literature on rituximab for MG, we conclude that preliminary data on the efficacy and safety of rituximab are encouraging and that further studies in MG seem warranted.

0 Bookmarks
 · 
64 Views
  • [Show abstract] [Hide abstract]
    ABSTRACT: This article provides a thorough overview of the current advances in diagnosis and therapy of myasthenia gravis (MG). Nowadays the term 'myasthenia gravis' includes heterogeneous autoimmune diseases with a postsynaptic defect of neuromuscular transmission as the common feature. Myasthenia gravis should be classified according to the antibody specificity (acetylcholine, MuSK, LRP4, seronegative), thymus histology (thymitis, thymoma, atrophy), age at onset (in children; < or > 40 years), and type of course (ocular or generalized). With optimal treatment, the prognosis is good in terms of daily functions, quality of life and survival. Symptomatic treatment with acetylcholine esterase inhibition is usually combined with immunosuppression. Azathioprine remains still the first choice for long-term immunosuppressive therapy. Alternative immunosuppressive options to azathioprine include ciclosporin, cyclophosphamide, methotrexate, mycophenolate mofetil, and tacrolimus. Rituximab is a promising new drug for severe generalized MG. Emerging therapy options include belimumab, eculizumab, and the granulocyte macrophage-colony-stimulating factor. One pilot study on etanercept has given disappointing results. For decades thymectomy has been performed in younger adults to improve non-paraneoplastic MG. However, controlled prospective studies on the suspected benefit of this surgical procedure are still lacking. In acute exacerbations including myasthenic crisis, intravenous immunoglobulin, plasmapheresis, and immunoadsorption are similarly effective.
    Clinical & Experimental Immunology 10/2013; · 3.41 Impact Factor
  • Source
    [Show abstract] [Hide abstract]
    ABSTRACT: Myasthenia gravis (MG) is the most common disorder of neuromuscular transmission and is a prototypical autoimmune disorder. Most patients with MG are successfully treated with acetylcholinesterase inhibitors, corticosteroids, and/or steroid sparing agents such as azathioprine and mycophenolate mofetil. There is a small subset of patients, however, with treatment-refractory disease. In these cases, medications such as rituximab, high-dose cyclophosphamide, and eculizumab may be used. Thymectomy (in some cases repeat thymectomy) is another option in selected patients. Studies evaluating these and other forms of therapy in treatment-refractory MG are reviewed.
    Journal of clinical neuromuscular disease. 06/2014; 15(4):167-78.
  • [Show abstract] [Hide abstract]
    ABSTRACT: Introduction: A subset of regulatory B cells in humans and mice has been defined functionally by their ability to produce interleukin (IL)-10. We characterized IL-10-producing B (B10) cells in myasthenia gravis (MG) patients and correlated them with disease activity and responsiveness to rituximab therapy. Methods: Frequencies of B10 cells from MG patients and healthy controls were monitored by fluorescence-activated cell sorting (FACS). Results: MG patients had fewer B10 cells than controls, which was associated with more severe disease status. Moreover, patients who responded well to rituximab therapy exhibited rapid repopulation of B10 cells, whereas in patients who did not respond well to rituximab, B10 cell repopulation was delayed. The kinetics of B10 cells were related to the responsiveness to rituximab in MG. Conclusion: We have characterized a specific subset of B10 cells in MG patients which may serve as a marker for MG activity and responsiveness to immune therapy. © 2013 Wiley Periodicals, Inc.
    Muscle & Nerve 07/2013; · 2.31 Impact Factor